Pastorino U, Valente M, Cataldo I, Lequaglie C, Ravasi G
Eur J Cancer Clin Oncol. 1986 Nov;22(11):1375-8. doi: 10.1016/0277-5379(86)90148-3.
Based on the experience of blood-related immunosuppression in kidney transplants, some retrospective studies have reported an adverse relationship between blood transfusion and survival after curative resection for cancer. In order to confirm these findings, we have retrospectively evaluated our population of resected stage Ia non-small cell lung cancers (years 1974-79). Two hundred and eighty-three patients were included in this analysis: 65 underwent pneumonectomy (23%), 205 lobectomy (72%) and 13 sublobar resections (5%). Patients submitted to perioperative blood transfusions were 157 (55%), without major differences according to surgery or tumour extent. The cumulative survival at 8 yr was 40% for transfused patients and 41% for nontransfused, relapse-free survival was respectively 36% and 34%; no differences were detectable stratifying for the amount of blood transfused or the extent of operation. Our experience does not support the hypothesis of an adverse prognosis related to perioperative blood transfusion.
基于肾移植中与输血相关的免疫抑制经验，一些回顾性研究报告了输血与癌症根治性切除术后生存率之间的不良关系。为了证实这些发现，我们对1974 - 1979年期间接受切除的Ia期非小细胞肺癌患者群体进行了回顾性评估。本分析纳入了283例患者：65例行肺切除术（23%），205例行肺叶切除术（72%），13例行肺段以下切除术（5%）。接受围手术期输血的患者有157例（55%），根据手术方式或肿瘤范围无显著差异。输血患者8年累计生存率为40%，未输血患者为41%；无复发生存率分别为36%和34%；按输血量或手术范围分层未发现差异。我们的经验不支持围手术期输血与不良预后相关的假设。
